Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

BACKGROUND: Nimotuzumab (NTZ) is an anti-EGFR monoclonal antibody. However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear. The aim of this study is to investigate the safety and efficacy of NTZ combined with cisplatin plus 5-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ying, Chen, Dagui, Liang, Jinhui, Gao, Jianquan, Luo, Zhanxiong, Wang, Rensheng, Liu, Wenqi, Huang, Changjie, Ning, Xuejian, Liu, Meilian, Huang, Haixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937916/
https://www.ncbi.nlm.nih.gov/pubmed/31888551
http://dx.doi.org/10.1186/s12885-019-6459-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937916/
https://www.ncbi.nlm.nih.gov/pubmed/31888551
http://dx.doi.org/10.1186/s12885-019-6459-6

Ejemplares similares